Oncotarget

Research Papers:

Combination therapy of 7-O-succinyl macrolactin A tromethamine salt and temozolomide against experimental glioblastoma

Jun Jin, Kihwan Hwang, Jin-Deok Joo, Jung Ho Han and Chae-Yong Kim _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:2140-2147. https://doi.org/10.18632/oncotarget.23295

Metrics: PDF 399 views  |   HTML 736 views  |   ?  


Abstract

Jun Jin1,2, Kihwan Hwang1, Jin-Deok Joo1, Jung Ho Han1,2 and Chae-Yong Kim1,2

1Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam-Si, Korea

2Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea

Correspondence to:

Chae-Yong Kim, email: chaeyong@snu.ac.kr

Keywords: glioblastoma; migration; invasion; macrolactin A; SMA salt

Received: September 07, 2017     Accepted: December 05, 2017     Published: December 14, 2017

ABSTRACT

7-O-succinyl macrolactin A has shown anti-inflammatory, anti-angiogenesis, and anti-metastatic effects. It also exhibits strong suppression of tumor growth. In our previous study, we assessed the anti-neoplastic effects of 7-O-succinyl macrolactin A tromethamine salt (SMA salt) on a glioma cell line. Moreover, according to our data, SMA salt might be contributed to the inhibitory effects on migration and invasion, as well as a cytotoxic effect on the glioblastoma cell lines. In the present study, we investigated the anti-tumor effects of combination therapy with SMA salt and temozolomide (TMZ) in glioblastoma cell lines. The combination therapy affected cell viability significantly, decreasing in glioblastoma cell lines. In cell migration assays, combination therapy showed more inhibitory effects than TMZ in these cell lines. The tumor volume was significantly decreased in the combination group compared with both TMZ and control groups by using the orthotopic mouse model. The effects of combination therapy with SMA salt and TMZ attributed to the inhibition of migration, invasion activities and anti-tumor effects. SMA salt could be one of the promising candidates for combination therapy in clinical settings.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23295